A5007497866- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Inhalation and Respiratory Drug Delivery
- Occupational and environmental lung diseases
- Air Quality and Health Impacts
- Diabetes Treatment and Management
- Delphi Technique in Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Occupational exposure and asthma
- Pneumonia and Respiratory Infections
- Pediatric health and respiratory diseases
- Pharmaceutical studies and practices
- Metabolism, Diabetes, and Cancer
- Pharmacological Effects and Assays
- Rheumatoid Arthritis Research and Therapies
- Allergic Rhinitis and Sensitization
- Pleural and Pulmonary Diseases
- Heart Failure Treatment and Management
- Transplantation: Methods and Outcomes
- Lung Cancer Diagnosis and Treatment
- School Health and Nursing Education
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Disease Management Strategies
Jewish General Hospital
2015-2024
McGill University
2015-2024
McGill University Health Centre
2000-2023
Université de Montréal
1997-2013
Christie (Canada)
2009
University of Ottawa
1988-2008
Royal Victoria Hospital
1985-2007
Royal Victoria Regional Health Centre
1985-2007
Hôpital du Sacré-Cœur de Montréal
2005-2007
Institut Paoli-Calmettes
2005
Morbidity and mortality from asthma appear to be increasing, it has been suggested that medications used treat are contributing this trend. We investigated a possible association between death or near the regular use of beta 2-agonist bronchodilators.Using linked health insurance data bases Saskatchewan, Canada, we conducted matched case-control study subjects drawn cohort 12,301 patients for whom had prescribed 1978 1987. 129 case who fatal near-fatal with 655 controls (who received but not...
Although inhaled corticosteroids are effective for the treatment of asthma, it is uncertain whether their use can prevent death from asthma.
<h3>Background</h3> The long-term natural history of chronic obstructive pulmonary disease (COPD) in terms successive severe exacerbations and mortality is unknown. <h3>Methods</h3> authors formed an inception cohort patients from their first ever hospitalisation for COPD during 1990–2005, using the healthcare databases province Quebec, Canada. Patients were followed until death or 31 March 2007, all hospitalisations occurring follow-up identified. hazard functions hospitalised all-cause...
Peroxynitrite is a potent oxidant formed by the rapid reaction of free radicals nitric oxide (NO) and superoxide. It causes airway hyperresponsiveness epithelial damage, enhances inflammatory cell recruitment, inhibits pulmonary surfactant. Asthma characterized increased hyperresponsiveness, shedding, inflammation. We examined production peroxynitrite expression inducible synthase (iNOS) in airways asthmatic patients compared to normal control subjects. also performed double-blind, crossover...
Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD). It is unclear whether varies for different inhaled agents, particularly fluticasone and budesonide, increases dose long-term duration use.We formed a new-user cohort COPD treated during 1990-2005. Subjects were identified using Quebec health insurance databases followed through 2007 or until serious event, defined as first hospitalisation death from...
The association between the use of inhaled beta-agonists and risk death near-death from asthma has previously been reported. It was based on a nested case-control study 129 cases 655 control subjects selected cohort 12,301 users drugs followed during period 1980 through 1987. In this paper we examine question non-asthma mortality using data entire asthmatics. There were 46 134 deaths in cohort, for which there 47,842 person-years follow-up. overall rate 9.6 per 10,000 asthmatics year. This...
Rationale: Inhaled corticosteroids are commonly prescribed to patients with chronic obstructive pulmonary disease (COPD).Objectives: To examine whether these medications might be associated an excess risk of pneumonia.Methods: We conducted a nested case-control study within cohort COPD from Quebec, Canada, over the period 1988–2003, identified on basis administrative databases linking hospitalization and drug-dispensing information. Each subject hospitalized for pneumonia during follow-up...
Rationale: Unreported exacerbations and failure to seek medical attention may have consequences on the health of patients with chronic obstructive pulmonary disease.Objectives: This study aims determine incidence reported unreported exacerbations, identify predictors reporting, compare impact status.Methods: The is based a multicenter Canadian cohort disease.Measurements Main Results: Patients completed daily diary from which were defined as worsening at least one key symptom (dyspnea,...
There is concern that antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase the risk of heart failure. Ongoing clinical trials may not have large enough samples to effectively address this issue. We applied a common protocol in analysis multiple cohorts patients with diabetes. used health care data from four Canadian provinces, United States, Kingdom. With use nested case-control analysis, we matched...
Background: Sodium–glucose cotransporter-2 (SGLT-2) inhibitors could increase the risk for diabetic ketoacidosis (DKA). Objective: To assess whether SGLT-2 inhibitors, compared with dipeptidyl peptidase-4 (DPP-4) are associated an increased DKA in patients type 2 diabetes. Design: Population-based cohort study; prevalent new-user design between 2013 and 2018. (ClinicalTrials.gov: NCT04017221) Setting: Electronic health care databases from 7 Canadian provinces United Kingdom. Patients: 208...
Long COVID, or post-acute COVID-19 syndrome, is characterized by multi-organ symptoms lasting 2+ months after initial virus infection. This review presents the current state of evidence for long COVID including global public health context, incidence, prevalence, cardiopulmonary sequelae, physical and mental symptoms, recovery time, prognosis, risk factors, rehospitalization rates, impact vaccination on outcomes. Results are presented clinically relevant subgroups. Overall, 10-35% survivors...
The PARI-IS Study is a double-blind placebo-controlled randomized clinical trial to study the effect of an immunostimulating agent prevent acute respiratory exacerbation in patients with COPD. Three hundred eighty-one ambulatory (190 placebo and 191 immunostimulant) were followed at home for 6 mo by experienced research nurses. risk having least one episode (primary outcome) was similar two groups (p = 0.872). In contrast, total number days hospitalization problem 55% less group treated...
The association between the use of inhaled beta-agonists by metered-dose inhaler and risk fatal or near-fatal asthma has been demonstrated. It shows that asthmatics who one canister beta-agonist per month more than number used other similar have twice asthma. present investigation assesses magnitude this excess when an asthmatic increases his/her own monthly over time. From a previous nested case-control study 129 deaths near-deaths from (cases) 655 controls cohort 12,301 asthmatics, subset...
The Asthma Committee of the Canadian Thoracic Society invited a group physicians with particular interest in asthma to meet Montebello, Quebec, March 9‐12, 1995 arrive at consensus statement on optimal approach management pediatric and adult ambulatory care settings. societies associations represented are listed appendix names contributors this document. objectives Montebello conference were: 1. To review current Canada; 2. develop guidelines participation family specialists; 3. which...
Abstract Objective Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated leflunomide, a disease‐modifying antirheumatic drug (DMARD), have been appearing recently. To assess this risk, we conducted population‐based epidemiologic study. Methods A cohort 62,734 RA to whom DMARD had dispensed between September 1, 1998 and December 31, 2003 was formed using the PharMetrics claims database. nested case–control design used, which each case...